Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers


Good Test Results at New York Health Care

A little-known company with no Wall Street following, New York Health Care (BBAL) shares have been active: They jumped from 2 in early July to 3.28 on Aug. 6. The reason: The company's Bio Balance unit has a proprietary product, Probactrix -- an oral liquid formulation -- that was effective in curbing AIDS-related diarrhea in a clinical study. As a result, Chief Operating Officer Dennis O'Donnell says the company will explore a prescription drug for AIDS-related diarrhea. It is developing treatments for other gastrointestinal disorders, including Crohn's disease. Orton Chen of RedChip Research notes that Probactrix is approved as an over-the-counter drug in Russia and as a food supplement in Israel. He says Probactrix will benefit from the recent focus on irritable bowel syndrome and antibiotic-associated diarrhea, which afflicts AIDS patients. O'Donnell notes that diarrhea will affect most of the 1 million Americans living with HIV. Chen says the stock deserves a p-e ratio of 35 -- in line other profitable biotechs. His target price: 8, based on his forecast that New York Health Care will earn 12 cents in 2004 and 36 cents in 2005.

Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them. By Gene G. Marcial

blog comments powered by Disqus